Literature DB >> 30692017

Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance.

Kun-Peng Zhu1, Chun-Lin Zhang2, Xiao-Long Ma1, Jian-Ping Hu1, Tao Cai1, Lei Zhang1.   

Abstract

Chemo-resistance is a huge obstacle encountered in the osteosarcoma (OS) treatment. Protein-coding mRNAs, as well as non-coding RNAs (ncRNAs), including long ncRNA (lncRNA), circular RNA (circRNA), and microRNA (miRNA), have been demonstrated to play an essential role in the regulation of cancer biology. However, the comprehensive expression profile and competing endogenous RNA (ceRNA) regulatory network between mRNAs and ncRNAs in the OS chemo-resistance still remain unclear. In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. Taken together, our findings may provide new evidence for the underlying mechanism of OS chemo-resistance and uncover some novel targets for reversing it.
Copyright © 2019 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ceRNA; chemo-resistance; mRNA; ncRNA; osteosarcoma

Mesh:

Substances:

Year:  2019        PMID: 30692017      PMCID: PMC6401193          DOI: 10.1016/j.ymthe.2019.01.001

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  44 in total

1.  Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis.

Authors:  Zhe Han; Liying Shi
Journal:  Biochem Biophys Res Commun       Date:  2017-11-21       Impact factor: 3.575

2.  Potent isozyme-selective inhibition of human glutathione S-transferase A1-1 by a novel glutathione S-conjugate.

Authors:  I Cacciatore; A M Caccuri; A Cocco; F De Maria; A Di Stefano; G Luisi; F Pinnen; G Ricci; P Sozio; P Turella
Journal:  Amino Acids       Date:  2005-08-08       Impact factor: 3.520

3.  Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.

Authors:  Jingjing Pan; Xu Li; Wenjing Wu; Mei Xue; Huilian Hou; Wen Zhai; Wei Chen
Journal:  Cancer Lett       Date:  2016-08-31       Impact factor: 8.679

Review 4.  Non-coding RNAs: Functions and applications in endocrine-related cancer.

Authors:  Thejaswini Venkatesh; Padmanaban S Suresh; Rie Tsutsumi
Journal:  Mol Cell Endocrinol       Date:  2015-09-07       Impact factor: 4.102

5.  Elevated expression of AKT2 correlates with disease severity and poor prognosis in human osteosarcoma.

Authors:  Yalong Zhu; Jianhua Zhou; Ying Ji; Baoqing Yu
Journal:  Mol Med Rep       Date:  2014-06-10       Impact factor: 2.952

6.  MEG3 long non-coding RNA prevents cell growth and metastasis of osteosarcoma.

Authors:  S Z Zhang; L Cai; B Li
Journal:  Bratisl Lek Listy       Date:  2017       Impact factor: 1.278

7.  The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.

Authors:  Youguang Pu; Fangfang Zhao; Yinpeng Li; Mingda Cui; Haiyan Wang; Xianghui Meng; Shanbao Cai
Journal:  BMC Cancer       Date:  2017-01-10       Impact factor: 4.430

Review 8.  Osteosarcoma: Accelerating Progress Makes for a Hopeful Future.

Authors:  Amanda J Saraf; Joelle M Fenger; Ryan D Roberts
Journal:  Front Oncol       Date:  2018-01-26       Impact factor: 6.244

9.  Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.

Authors:  Zhengguang Wang; Zhendong Liu; Song Wu
Journal:  Oncotarget       Date:  2017-05-09

10.  miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.

Authors:  Yong Zhou; Zufa Huang; Song Wu; Xiaofang Zang; Min Liu; Jian Shi
Journal:  J Exp Clin Cancer Res       Date:  2014-01-27
View more
  50 in total

1.  miR-376a inhibits the proliferation and invasion of osteosarcoma by targeting FBXO11.

Authors:  Qiaolong Xu; Li Cheng; Jianyang Chen; Wenjie Lu; Peinian Wang
Journal:  Hum Cell       Date:  2019-05-11       Impact factor: 4.174

2.  The regulatory mechanism of LncRNA-mediated ceRNA network in osteosarcoma.

Authors:  Chengsen Lin; Jifeng Miao; Shijie Liao; Yun Liu; Juliang He; Wenyu Feng; Xianxiang Chen; Xiaohong Jiang; Jianhong Liu; Boxiang Li; Qian Huang
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

3.  Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer.

Authors:  Mengmeng Jiang; Wenwen Zhang; Rui Zhang; Pengpeng Liu; Yingnan Ye; Wenwen Yu; Xiaojing Guo; Jinpu Yu
Journal:  Oncogene       Date:  2020-05-12       Impact factor: 9.867

4.  The Circular RNA circSKA3 Binds Integrin β1 to Induce Invadopodium Formation Enhancing Breast Cancer Invasion.

Authors:  William W Du; Weining Yang; Xiangmin Li; Ling Fang; Nan Wu; Feiya Li; Yu Chen; Qihan He; Elizabeth Liu; Zhenguo Yang; Faryal Mehwish Awan; Mingyao Liu; Burton B Yang
Journal:  Mol Ther       Date:  2020-03-10       Impact factor: 11.454

5.  Overexpressing microRNA-203 alleviates myocardial infarction via interacting with long non-coding RNA MIAT and mitochondrial coupling factor 6.

Authors:  Fan Wang; Renliang Yu; Shengnan Wen; Jie Yin; Yugen Shi; Hesheng Hu; Suhua Yan
Journal:  Arch Pharm Res       Date:  2021-05-04       Impact factor: 4.946

6.  Hsa_circ_0010220 regulates miR-198/Syntaxin 6 axis to promote osteosarcoma progression.

Authors:  Zhaoan Lu; Chuanwen Wang; Xiaolong Lv; Wen Dai
Journal:  J Bone Oncol       Date:  2021-04-22       Impact factor: 4.072

Review 7.  Circular RNAs: new biomarkers of chemoresistance in cancer.

Authors:  Jiaqi Wang; Yi Zhang; Lianyu Liu; Ting Yang; Jun Song
Journal:  Cancer Biol Med       Date:  2021-03-19       Impact factor: 4.248

8.  The whole profiling and competing endogenous RNA network analyses of noncoding RNAs in adipose-derived stem cells from diabetic, old, and young patients.

Authors:  Sen Ren; Hewei Xiong; Jing Chen; Xiaofan Yang; Yutian Liu; Jiahe Guo; Tao Jiang; Zhao Xu; Meng Yuan; Yang Liu; Nan Zhou; Hongrui Chen; Wenqing Li; Hans-Günther Machens; Zhenbing Chen
Journal:  Stem Cell Res Ther       Date:  2021-05-29       Impact factor: 6.832

9.  Development of a Novel Immune Infiltration-Related ceRNA Network and Prognostic Model for Sarcoma.

Authors:  Deyao Shi; Shidai Mu; Feifei Pu; Binlong Zhong; Binwu Hu; Jianxiang Liu; Tongchuan He; Zhicai Zhang; Zengwu Shao
Journal:  Front Cell Dev Biol       Date:  2021-07-01

10.  Hsa_circRNA_000543 Predicts Poor Prognosis and Promotes Cervical Cancer Cell Progression Through Regulating miR-567/ZNF268 Axis.

Authors:  Zhilan Yao; Liuping Shu; Yi Yi; Lifu Qiao
Journal:  Cancer Manag Res       Date:  2021-06-30       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.